Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer (GlobeNewswire) - Jul 2, 2024 - "Plus Therapeutics, Inc...announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m. EDT at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine. The presentation will report data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM)."
P1 data • P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|